JP2014240385A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014240385A5 JP2014240385A5 JP2014115617A JP2014115617A JP2014240385A5 JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5 JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014115617 A JP2014115617 A JP 2014115617A JP 2014240385 A5 JP2014240385 A5 JP 2014240385A5
- Authority
- JP
- Japan
- Prior art keywords
- mab
- fgfr2iiic
- inhibits
- fgfr2iiib
- binds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 241000699670 Mus sp. Species 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 241000699666 Mus <mouse, genus> Species 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11268608P | 2008-11-07 | 2008-11-07 | |
| US61/112,686 | 2008-11-07 | ||
| US16487009P | 2009-03-30 | 2009-03-30 | |
| US61/164,870 | 2009-03-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534932A Division JP5627591B2 (ja) | 2008-11-07 | 2009-11-06 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152670A Division JP6445496B2 (ja) | 2008-11-07 | 2016-08-03 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014240385A JP2014240385A (ja) | 2014-12-25 |
| JP2014240385A5 true JP2014240385A5 (OSRAM) | 2015-02-12 |
| JP6342223B2 JP6342223B2 (ja) | 2018-06-13 |
Family
ID=42153600
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534932A Active JP5627591B2 (ja) | 2008-11-07 | 2009-11-06 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2014115617A Active JP6342223B2 (ja) | 2008-11-07 | 2014-06-04 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2016152670A Active JP6445496B2 (ja) | 2008-11-07 | 2016-08-03 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2018223183A Active JP6661734B2 (ja) | 2008-11-07 | 2018-11-29 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2020018719A Active JP6960485B2 (ja) | 2008-11-07 | 2020-02-06 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2021166672A Active JP7301106B2 (ja) | 2008-11-07 | 2021-10-11 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2023100475A Pending JP2023116746A (ja) | 2008-11-07 | 2023-06-20 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2024193584A Pending JP2025032085A (ja) | 2008-11-07 | 2024-11-05 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011534932A Active JP5627591B2 (ja) | 2008-11-07 | 2009-11-06 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016152670A Active JP6445496B2 (ja) | 2008-11-07 | 2016-08-03 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2018223183A Active JP6661734B2 (ja) | 2008-11-07 | 2018-11-29 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2020018719A Active JP6960485B2 (ja) | 2008-11-07 | 2020-02-06 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2021166672A Active JP7301106B2 (ja) | 2008-11-07 | 2021-10-11 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2023100475A Pending JP2023116746A (ja) | 2008-11-07 | 2023-06-20 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
| JP2024193584A Pending JP2025032085A (ja) | 2008-11-07 | 2024-11-05 | 線維芽増殖因子受容体２に対するモノクローナル抗体 |
Country Status (20)
| Country | Link |
|---|---|
| US (8) | US8101723B2 (OSRAM) |
| EP (4) | EP2365828B1 (OSRAM) |
| JP (8) | JP5627591B2 (OSRAM) |
| KR (1) | KR101699432B1 (OSRAM) |
| CN (1) | CN102131524B (OSRAM) |
| AU (1) | AU2009313357B2 (OSRAM) |
| BR (1) | BRPI0917315B8 (OSRAM) |
| CA (2) | CA3166399A1 (OSRAM) |
| DK (3) | DK2842573T3 (OSRAM) |
| ES (3) | ES2646168T3 (OSRAM) |
| HR (2) | HRP20171640T1 (OSRAM) |
| HU (1) | HUE035700T2 (OSRAM) |
| LT (2) | LT2842573T (OSRAM) |
| MX (1) | MX2011000455A (OSRAM) |
| NO (1) | NO2842573T3 (OSRAM) |
| PL (3) | PL2842573T3 (OSRAM) |
| PT (3) | PT3290052T (OSRAM) |
| RU (1) | RU2546254C9 (OSRAM) |
| SI (2) | SI3290052T1 (OSRAM) |
| WO (1) | WO2010054265A2 (OSRAM) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9260525B2 (en) | 2008-02-04 | 2016-02-16 | Xiao-Jia Chang | Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof |
| WO2009100105A2 (en) * | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| DK2842573T3 (en) | 2008-11-07 | 2017-10-30 | Galaxy Biotech Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
| SG185487A1 (en) * | 2010-05-11 | 2012-12-28 | Aveo Pharmaceuticals Inc | Anti-fgfr2 antibodies |
| EP2603521A4 (en) * | 2010-08-12 | 2014-10-01 | Attogen Inc | ANTIBODY MOLECULARS FOR ONGOGEN FIBROBLAST GROWTH RECEPTOR 2 ISOFORMS AND ITS USES |
| EP2710042A2 (en) | 2011-05-16 | 2014-03-26 | Fabion Pharmaceuticals, Inc. | Multi-specific fab fusion proteins and methods of use |
| AR088941A1 (es) | 2011-11-23 | 2014-07-16 | Bayer Ip Gmbh | Anticuerpos anti-fgfr2 y sus usos |
| SG11201403085PA (en) | 2011-12-14 | 2014-10-30 | Seattle Genetics Inc | Fgfr antibody drug conjugates (adcs) and the use thereof |
| EA028433B1 (ru) | 2012-03-08 | 2017-11-30 | Янссен Вэксинс Энд Превеншн Б.В. | Антитело, связывающееся с вирусами гриппа b и его применение |
| CA2870126C (en) | 2012-04-09 | 2020-10-27 | Daiichi Sankyo Company, Limited | Anti-fgfr2 antibody |
| WO2014089193A1 (en) * | 2012-12-04 | 2014-06-12 | Aveo Pharmaceuticals, Inc. | Anti-fgfr2 antibodies |
| DK2936153T3 (en) * | 2012-12-21 | 2019-02-25 | Janssen Biotech Inc | SENSITIVE MULTIPLEX IMMUNOASSAY FOR SOLUBLE FIBROBLAST GROWTH FACTOR RECEPTORS |
| CN103145843B (zh) * | 2013-02-20 | 2014-10-29 | 暨南大学 | 抗成纤维细胞生长因子受体的单链抗体 |
| KR20150123250A (ko) | 2013-03-06 | 2015-11-03 | 제넨테크, 인크. | 암 약물 내성의 치료 및 예방 방법 |
| PE20160190A1 (es) * | 2013-08-01 | 2016-04-28 | Five Prime Therapeutics Inc | Anticuerpos anti-fgfr2iiib afucosilados |
| ES2768618T3 (es) * | 2013-10-08 | 2020-06-23 | Daiichi Sankyo Co Ltd | Combinación de anticuerpo anti-FGFR2 y otro agente |
| CN103757026B (zh) * | 2013-12-20 | 2017-04-05 | 广州圣露生物技术有限公司 | FGFR2b胞外段的基因序列、多肽及其应用 |
| JP2017517552A (ja) | 2014-06-13 | 2017-06-29 | ジェネンテック， インコーポレイテッド | 抗癌剤耐性の治療及び防止方法 |
| CN104231079A (zh) * | 2014-09-12 | 2014-12-24 | 暨南大学 | 一种靶向bFGF高亲和力受体结合位点的抗体及其应用 |
| TW201642904A (zh) * | 2015-04-08 | 2016-12-16 | 第一三共股份有限公司 | 含抗ｆｇｆｒ２抗體及其他藥劑之組成物 |
| WO2016171107A1 (ja) | 2015-04-20 | 2016-10-27 | 第一三共株式会社 | Ｆｇｆｒ２の検出 |
| RU2638457C2 (ru) * | 2015-09-28 | 2017-12-13 | Общество С Ограниченной Ответственностью "Онкомакс" | Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител |
| BR112018010410A8 (pt) * | 2015-11-23 | 2019-02-26 | Five Prime Therapeutics Inc | método para tratar câncer em um sujeito, composição e métodos de aumento do número de células nk e de aumento do número de uma ou mais células positivas para pd-l1 |
| JP7034489B2 (ja) | 2016-03-15 | 2022-03-14 | アイタブメッド （エイチケイ） リミテッド | 多重特異性Ｆａｂ融合タンパクおよびその使用 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CN110621336B (zh) | 2017-05-16 | 2024-05-14 | 戊瑞治疗有限公司 | 癌症治疗中抗fgfr2抗体与化学治疗剂的组合 |
| CN110997716B (zh) | 2017-06-02 | 2024-03-15 | 埃博灵克斯股份有限公司 | 结合聚集蛋白聚糖的免疫球蛋白 |
| WO2019084067A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | ANTI-CD117 ANTIBODIES AND METHODS OF USE |
| CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| EP3860563A1 (en) | 2018-10-05 | 2021-08-11 | Five Prime Therapeutics, Inc. | Anti-fgfr2 antibody formulations |
| WO2021129656A1 (en) * | 2019-12-24 | 2021-07-01 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | Novel anti-fgfr2b antibodies |
| EP4081547A4 (en) * | 2019-12-24 | 2024-02-21 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. | NOVEL ANTI-FGFR2B ANTIBODIES |
| CA3185812A1 (en) * | 2020-06-03 | 2021-12-09 | The Broad Institute, Inc. | Antagonistic biparatopic antibodies that specifically bind fibroblast growth factor receptor 2 and methods of using same |
| KR20230095070A (ko) | 2020-10-22 | 2023-06-28 | 리제너론 파마슈티칼스 인코포레이티드 | 항-fgfr2 항체 및 이의 사용 방법 |
| TW202241951A (zh) * | 2020-12-29 | 2022-11-01 | 大陸商深圳福沃藥業有限公司 | 抗ｆｇｆｒ２抗體及其用途 |
| US20250277041A1 (en) * | 2021-10-08 | 2025-09-04 | Shenzhen Forward Pharmaceuticals Co., Limited | Anti-fgfr2 adcc enhanced antibody and use thereof |
| TW202342527A (zh) | 2022-02-25 | 2023-11-01 | 美商安進公司 | 鱗狀非小細胞肺癌之治療 |
| EP4594356A1 (en) * | 2022-09-30 | 2025-08-06 | 3H Pharmaceuticals Co., Ltd. | Anti-fgfr2b antibodies and uses thereof |
| TW202442685A (zh) * | 2023-04-28 | 2024-11-01 | 大陸商武漢人福創新藥物研發中心有限公司 | 抗FGFR2b單抗 |
| CN118994393A (zh) * | 2023-05-19 | 2024-11-22 | 广东东阳光药业股份有限公司 | 一种抗fgfr2抗体及其应用 |
| WO2024255756A1 (zh) * | 2023-06-13 | 2024-12-19 | 南京维立志博生物科技股份有限公司 | 基于共同轻链产生双特异性抗体的方法 |
| TW202527998A (zh) * | 2023-12-18 | 2025-07-16 | 大陸商山東先聲生物製藥有限公司 | 抗FGFR2b抗體-藥物綴合物及其應用 |
| WO2025218662A1 (zh) * | 2024-04-16 | 2025-10-23 | 杭州中美华东制药有限公司 | 抗成纤维细胞生长因子受体2b的抗体及其用途 |
| WO2025232811A1 (zh) * | 2024-05-09 | 2025-11-13 | 正大天晴药业集团股份有限公司 | 靶向成纤维细胞生长因子受体2IIIb的抗体及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE69033109T2 (de) | 1989-07-06 | 1999-11-18 | The Regents Of The University Of California, Oakland | Rezeptoren für fibroblasten-wachstumsfaktoren |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5863888A (en) | 1990-07-06 | 1999-01-26 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Human Bek Fibroblast growth factor receptor |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US6066718A (en) | 1992-09-25 | 2000-05-23 | Novartis Corporation | Reshaped monoclonal antibodies against an immunoglobulin isotype |
| NZ275711A (en) * | 1993-10-14 | 1998-03-25 | Immunex Corp | Monoclonal antibodies and binding proteins which bind to human fas antigen (nerve growth factor/tumour necrosis factor receptor type) |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| AU3494397A (en) | 1996-06-18 | 1998-01-07 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Fibroblast growth factor receptor activating gene i and related compositions and methods |
| US20030143676A1 (en) * | 1999-03-25 | 2003-07-31 | Genesis Research And Development Corporation Limited | Fibroblast growth factor receptors and methods for their use |
| CN1308347C (zh) * | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| JP2001302699A (ja) | 2000-04-17 | 2001-10-31 | Nichirei Corp | ヒトｋｇｆｒに対する抗体 |
| US20020115603A1 (en) | 2000-06-22 | 2002-08-22 | Chiron Corporation | Methods and compositions for the treatment of peripheral artery disease |
| CZ200438A3 (cs) * | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
| IL159177A0 (en) | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
| ES2363765T3 (es) | 2002-01-31 | 2011-08-16 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Agonistas de fgfr. |
| KR100493460B1 (ko) * | 2002-08-29 | 2005-06-07 | 재단법인서울대학교산학협력재단 | 암 세포에서 발현되는 ｆｇｆｒ2 이성체 |
| US7220410B2 (en) | 2003-04-18 | 2007-05-22 | Galaxy Biotech, Llc | Monoclonal antibodies to hepatocyte growth factor |
| RS53476B (sr) | 2003-07-18 | 2014-12-31 | Amgen Fremont Inc. | Sredstva za specifično vezivanje faktora rasta hepatocita |
| CA2550245A1 (en) * | 2003-12-19 | 2005-07-21 | Five Prime Therapeutics, Inc. | Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention |
| WO2005115363A2 (en) | 2004-05-25 | 2005-12-08 | Yale University | Method for treating skeletal disorders resulting from fgfr malfunction |
| CA2648021A1 (en) | 2006-03-31 | 2007-10-11 | Ordway Research Institute, Inc. | Prognostic and diagnostic method for cancer therapy |
| AR059922A1 (es) | 2006-04-01 | 2008-05-07 | Galaxy Biotech Llc | Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos |
| JP2009536834A (ja) * | 2006-05-12 | 2009-10-22 | ジェネンテック・インコーポレーテッド | 癌の診断及び治療のための方法及び組成物 |
| AU2007254853B2 (en) | 2006-06-02 | 2011-11-17 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| AU2007254942B2 (en) | 2006-06-02 | 2011-10-27 | Aveo Pharmaceuticals, Inc. | Hepatocyte growth factor (HGF) binding proteins |
| CA2655504A1 (en) | 2006-06-15 | 2007-12-21 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
| US7750124B2 (en) | 2006-09-29 | 2010-07-06 | Oncomed Pharmaceuticals, Inc. | Anti-human DLL4 antibodies and compositions |
| WO2008052796A1 (en) * | 2006-11-03 | 2008-05-08 | U3 Pharma Gmbh | Fgfr4 antibodies |
| JP2010525301A (ja) * | 2007-03-23 | 2010-07-22 | ザ・トランスレーショナル・ジェノミクス・リサーチ・インスティチュート | 子宮内膜癌および前癌の診断、分類および治療の方法 |
| US20110091473A1 (en) | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
| WO2009100105A2 (en) | 2008-02-04 | 2009-08-13 | Attogen Inc. | Inhibitors of oncogenic isoforms and uses thereof |
| EP2177615A1 (en) | 2008-10-10 | 2010-04-21 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases |
| DK2842573T3 (en) | 2008-11-07 | 2017-10-30 | Galaxy Biotech Llc | Monoclonal antibodies to fibroblast growth factor receptor 2 |
| WO2011025814A1 (en) | 2009-08-25 | 2011-03-03 | National Jewish Health | Methods and compositions for treatment of lung injury |
-
2009
- 2009-11-06 DK DK14188785.1T patent/DK2842573T3/en active
- 2009-11-06 EP EP09825523.5A patent/EP2365828B1/en active Active
- 2009-11-06 CA CA3166399A patent/CA3166399A1/en active Pending
- 2009-11-06 DK DK17191118.3T patent/DK3290052T3/da active
- 2009-11-06 WO PCT/US2009/063647 patent/WO2010054265A2/en not_active Ceased
- 2009-11-06 SI SI200932035T patent/SI3290052T1/sl unknown
- 2009-11-06 HU HUE14188785A patent/HUE035700T2/en unknown
- 2009-11-06 CA CA2733668A patent/CA2733668C/en active Active
- 2009-11-06 PL PL14188785T patent/PL2842573T3/pl unknown
- 2009-11-06 CN CN200980132269.2A patent/CN102131524B/zh active Active
- 2009-11-06 SI SI200931763T patent/SI2842573T1/en unknown
- 2009-11-06 ES ES14188785.1T patent/ES2646168T3/es active Active
- 2009-11-06 AU AU2009313357A patent/AU2009313357B2/en active Active
- 2009-11-06 PL PL09825523T patent/PL2365828T3/pl unknown
- 2009-11-06 PL PL17191118T patent/PL3290052T3/pl unknown
- 2009-11-06 DK DK09825523.5T patent/DK2365828T3/en active
- 2009-11-06 NO NO14188785A patent/NO2842573T3/no unknown
- 2009-11-06 PT PT171911183T patent/PT3290052T/pt unknown
- 2009-11-06 PT PT141887851T patent/PT2842573T/pt unknown
- 2009-11-06 LT LTEP14188785.1T patent/LT2842573T/lt unknown
- 2009-11-06 RU RU2011141890/10A patent/RU2546254C9/ru active
- 2009-11-06 US US12/614,282 patent/US8101723B2/en active Active
- 2009-11-06 ES ES09825523.5T patent/ES2523740T3/es active Active
- 2009-11-06 ES ES17191118T patent/ES2770134T3/es active Active
- 2009-11-06 LT LTEP17191118.3T patent/LT3290052T/lt unknown
- 2009-11-06 KR KR1020117002577A patent/KR101699432B1/ko active Active
- 2009-11-06 PT PT98255235T patent/PT2365828E/pt unknown
- 2009-11-06 EP EP19193727.5A patent/EP3783024A1/en active Pending
- 2009-11-06 BR BRPI0917315A patent/BRPI0917315B8/pt active IP Right Grant
- 2009-11-06 EP EP17191118.3A patent/EP3290052B1/en active Active
- 2009-11-06 MX MX2011000455A patent/MX2011000455A/es active IP Right Grant
- 2009-11-06 EP EP14188785.1A patent/EP2842573B1/en active Active
- 2009-11-06 JP JP2011534932A patent/JP5627591B2/ja active Active
-
2011
- 2011-10-28 US US13/284,838 patent/US8603987B2/en active Active
-
2013
- 2013-11-04 US US14/071,520 patent/US9382324B2/en active Active
-
2014
- 2014-06-04 JP JP2014115617A patent/JP6342223B2/ja active Active
-
2016
- 2016-06-02 US US15/172,033 patent/US9834609B2/en active Active
- 2016-08-03 JP JP2016152670A patent/JP6445496B2/ja active Active
-
2017
- 2017-08-10 US US15/674,385 patent/US10138301B2/en active Active
- 2017-10-26 HR HRP20171640TT patent/HRP20171640T1/hr unknown
-
2018
- 2018-10-18 US US16/164,530 patent/US10689448B2/en active Active
- 2018-11-29 JP JP2018223183A patent/JP6661734B2/ja active Active
-
2020
- 2020-01-20 HR HRP20200090TT patent/HRP20200090T1/hr unknown
- 2020-02-06 JP JP2020018719A patent/JP6960485B2/ja active Active
- 2020-05-05 US US16/867,398 patent/US20200347141A1/en not_active Abandoned
-
2021
- 2021-10-11 JP JP2021166672A patent/JP7301106B2/ja active Active
-
2023
- 2023-03-10 US US18/182,242 patent/US20230242650A1/en active Pending
- 2023-06-20 JP JP2023100475A patent/JP2023116746A/ja active Pending
-
2024
- 2024-11-05 JP JP2024193584A patent/JP2025032085A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014240385A5 (OSRAM) | ||
| CY1122840T1 (el) | Ανθρωποποιημενα ή χιμαιρικα αντισωματα cd3 | |
| CY1124771T1 (el) | Αντισωματα εναντι-σορτιλiνης και μεθοδοι χρησης αυτων | |
| ES2523194T3 (es) | Anticuerpo monoclonal humano específico para cada tumor | |
| JP2019518742A5 (OSRAM) | ||
| MX2017004311A (es) | Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos. | |
| JP2013198490A5 (OSRAM) | ||
| EP3712178A4 (en) | ANTI-HER2 ANTIBODIES OR ANTIGIBODY FRAGMENT THEREOF AND CHIMERAIR ANTIGEN RECEPTOR WITH IT | |
| EP4477269A3 (en) | Monoclonal antibodies specific for fibroblast growth factor receptor 4 (fgfr4) and methods of their use | |
| ES2776179T3 (es) | Anticuerpos dirigidos contra determinantes de la superficie de S. aureus | |
| JP2014205674A5 (OSRAM) | ||
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| IL291545A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof | |
| WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
| EP4048309A4 (en) | HUMANIZED ANTIBODIES AGAINST TNF-LIKE LIGAND 1A (TL1A) AND THEIR USES | |
| WO2016201389A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| WO2016201388A3 (en) | Anti-cd33 antibodies and methods of use thereof | |
| EP3929214A4 (en) | ANTIBODY OR CHIMERIC ANTIGEN RECEPTOR TARGETING CLAUDIN 18.2 | |
| MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
| EA201890305A1 (ru) | Гуманизированные или химерные cd3-антитела | |
| MX2015004105A (es) | Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso. | |
| MX359794B (es) | Anticuerpos anti-hepcidina y usos de los mismos. | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| PE20181054A1 (es) | Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion | |
| EP4032550A3 (en) | Humanized anti-cd19 antibody and use thereof with chimeric antigen receptor |